

Durvalumab HIMALAYA

PRELIMINARY SCORE

CURATIVE




NON-CURATIVE



OS non-inferiority

ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Other adjustments



Durvalumab HIMALAYA

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Durvalumab as monotherapy indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
Experimental Arm: Durvalumab
Control Arm: Sorafenib

